Axa S.A. Sells 63,373 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

AXA S.A. lowered its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 26.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 175,377 shares of the biopharmaceutical company's stock after selling 63,373 shares during the quarter. AXA S.A. owned about 0.31% of Agios Pharmaceuticals worth $5,763,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. Venturi Wealth Management LLC bought a new position in shares of Agios Pharmaceuticals in the fourth quarter valued at approximately $33,000. Wingate Wealth Advisors Inc. bought a new position in Agios Pharmaceuticals during the 4th quarter valued at $53,000. Sterling Capital Management LLC raised its stake in shares of Agios Pharmaceuticals by 818.0% in the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock worth $59,000 after buying an additional 1,587 shares in the last quarter. KBC Group NV boosted its stake in Agios Pharmaceuticals by 30.5% during the fourth quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock valued at $86,000 after buying an additional 611 shares in the last quarter. Finally, AlphaQuest LLC boosted its stake in Agios Pharmaceuticals by 106.2% during the fourth quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company's stock valued at $149,000 after buying an additional 2,338 shares in the last quarter.

Insider Activity at Agios Pharmaceuticals

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, April 10th. The stock was sold at an average price of $25.90, for a total transaction of $194,172.30. Following the completion of the sale, the director now directly owns 149,220 shares in the company, valued at $3,864,798. The trade was a 4.78 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.93% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. StockNews.com raised shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday. HC Wainwright initiated coverage on shares of Agios Pharmaceuticals in a report on Monday, February 24th. They set a "buy" rating and a $58.00 target price for the company. Finally, Scotiabank decreased their price target on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a research report on Friday, May 2nd. Five investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, Agios Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $56.00.

Agios Pharmaceuticals Trading Down 2.6 %

NASDAQ:AGIO traded down $0.72 during trading hours on Friday, hitting $27.32. 303,182 shares of the stock traded hands, compared to its average volume of 696,244. The firm has a 50 day moving average price of $29.23 and a 200 day moving average price of $37.27. The firm has a market cap of $1.58 billion, a price-to-earnings ratio of 2.41 and a beta of 0.77. Agios Pharmaceuticals, Inc. has a fifty-two week low of $23.42 and a fifty-two week high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, topping analysts' consensus estimates of ($1.80) by $0.25. The firm had revenue of $8.73 million during the quarter, compared to analyst estimates of $9.86 million. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. Research analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.